^
    Apply
    JS001+IMP4297 in Patients With Advanced Cancer (NCT05262842)
    Phase 1
    Shanghai Junshi Bioscience Co., Ltd.
    Withdrawn
    Last update posted :
    09/21/2022
    Initiation :
    03/29/2022
    Primary completion :
    04/06/2024
    Completion :
    06/06/2024
    HER-2 • PD-L1 • HRD • CDK4
    |
    HR positive • HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi) • Paxonin (senaparib)
    Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment (NCT04822961)
    Phase 2
    Impact Therapeutics, Inc.
    Not yet recruiting
    Last update posted :
    12/16/2021
    Initiation :
    12/31/2021
    Primary completion :
    05/01/2024
    Completion :
    08/01/2024
    BRCA1 • BRCA2 • HRD
    |
    docetaxel • Paxonin (senaparib)
    A Study of IMP4297 in Patients With Advanced Solid Tumors (NCT03508011)
    Phase 1
    Impact Therapeutics, Inc.
    Completed
    Last update posted :
    03/30/2021
    Initiation :
    08/23/2017
    Primary completion :
    12/16/2020
    Completion :
    12/16/2020
    BRCA
    |
    BRCA mutation
    |
    Paxonin (senaparib)
    The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors (NCT03507543)
    Phase 1
    Impact Therapeutics, Inc.
    Completed
    Last update posted :
    03/30/2021
    Initiation :
    02/03/2017
    Primary completion :
    09/24/2020
    Completion :
    03/17/2021
    BRCA
    |
    BRCA mutation
    |
    Paxonin (senaparib)
    Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (SABRINA) (NCT04089189)
    Phase 2
    Impact Therapeutics, Inc.
    Recruiting
    Last update posted :
    11/24/2020
    Initiation :
    09/11/2019
    Primary completion :
    03/01/2022
    Completion :
    08/01/2022
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Paxonin (senaparib)
    A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (FLAMES) (NCT04169997)
    Phase 3
    Impact Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/12/2020
    Initiation :
    12/24/2019
    Primary completion :
    02/28/2022
    Completion :
    12/30/2022
    BRCA • MUC16
    |
    BRCA mutation
    |
    cisplatin • Paxonin (senaparib)